The new disease-fighting cells are infused back into the patient's bloodstream.
At this stage clinical diagnostic testing will also track the immune response of the patient to the treatment. Blood tests will help determine which patients will respond to Immunotherapy. Tests can measures the levels of immune cell in the blood, and identify which cancer patients are most likely to respond to immunotherapy.
The success of immunotherapy has led to a myriad of clinical trials accompanied by efforts to gain mechanistic insight and identify predictive signatures for personalization. However, many immune monitoring technologies face investigator bias, missing unanticipated cellular responses in limited clinical material.
Your challenges
- Are your flow cytometry panel and flow cytometer reliable for dim populations?
-
How to automate small sample analysis for ctDNA assays?
Our Solutions for your Workflow
Preanalytic
Analytic
- Clinical Chemistry
- IVD Flowcytometry
- Hematology
- Immuno-hematology
- Immunoassay
- Molecular diagnostics
- Urine Analysis
Data Management
Sample Storage
Since many years, Analis has worked in close cooperation with its supplier and partner Beckman Coulter to propose a large range of instruments in the clinical laboratory field.
As an example, important clinical chemistry parameters such Liver test ,C-reactive protein , NS Blood glucose, Na, K, HCO3, Ca, serum creatinin, sample proteinuria / creatininuria ratio are easily achievable on the Beckman Coulter AU family clinical chemistry analyzers.
Immunoassay parameters such HBV, HCV, HIV Serologies , Anti-nuclear antibodies,TSH, T4, anti-thyroid antibodies are easily to perform on the Beckman Coulter Access Immunoassay Family analyzers.
Together we are focused on providing our customers innovative and flexible solutions to increase productivity, improve quality of results and simplify the process in clinical laboratories.
Contact an Expert
Sources and references
M. Kostine, L. Chiche, E. Lazaro, P. Halfon, C. Charpin, D. Arniaud, F. Retornaz, P. Blanco, N. Jourde-Chiche, C. Richez, C. Stavris, (2017). Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge, La Revue de Médecine Interne, Volume 38, Issue 8, Pages 513-525, ISSN 0248-8663.
https://doi.org/10.1016/j.revmed.2017.01.004
.